巴瑞替尼治疗住院成人COVID-19的疗效与安全性(COV-BARRIER):一项随机、双盲、平行组、安慰剂对照III期试验
严重不良事件、严重感染和静脉血栓栓塞事件两组相似。
要点
- 严重不良事件(15% vs 18%)、严重感染(9% vs 10%)和静脉血栓栓塞事件(3% vs 3%)两组相似。
- 主要终点未达统计学显著,死亡率获益为关键次要终点和探索性终点,解读需谨慎。
适用人群与场景
- 住院成人COVID-19患者,接受标准治疗(包括全身糖皮质激素如地塞米松和抗病毒药物如瑞德西韦)。
- 研究纳入来自亚洲、欧洲、北美和南美12个国家101个中心的患者。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 巴瑞替尼4mg口服每日一次,最多14天,联合标准治疗(包括地塞米松和瑞德西韦等)。
红旗征与不能漏的情况
- 原文未提及需要立即处理或不能漏诊的红旗征。
研究设计与关键结果
- III期双盲随机安慰剂对照试验,1525例住院成人COVID-19患者随机1:1接受巴瑞替尼4mg每日一次(n=764)或安慰剂(n=761),最多14天。
- 严重不良事件巴瑞替尼组15%(110/750)vs 安慰剂组18%(135/752);严重感染9%(64/750)vs 10%(74/752);静脉血栓栓塞事件3%(20/750)vs 3%(19/752)。
证据类型、等级与局限
- 证据类型:随机、双盲、平行组、安慰剂对照III期试验。
- 主要终点未达统计学显著,死亡率获益为关键次要终点(28天)和探索性终点(60天),名义P值未校正多重比较。
- 局限性:由Eli Lilly and Company资助;原文未提及其他局限性。
对床旁实践的改变
- 对于住院成人COVID-19患者,在标准治疗(包括地塞米松)基础上加用巴瑞替尼4mg每日一次最多14天,可能降低28天和60天全因死亡率,但未显著减少疾病进展复合终点。
- 严重不良事件、严重感染和静脉血栓栓塞事件发生率与安慰剂相似。
- 主要终点未达显著,死亡率获益来自次要和探索性终点,临床决策需结合个体情况。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-inflammatory properties. This study evaluates the efficacy and safety of baricitinib in combination with standard of care for the treatment of hospitalised adults with COVID-19.
METHODS: In this phase 3, double-blind, randomised, placebo-controlled trial, participants were enrolled from 101 centres across 12 countries in Asia, Europe, North America, and South America. Hospitalised adults with COVID-19 receiving standard of care were randomly assigned (1:1) to receive once-daily baricitinib (4 mg) or matched placebo for up to 14 days. Standard of care included systemic corticosteroids, such as dexamethasone, and antivirals, including remdesivir. The composite primary endpoint was the proportion who progressed to high-flow oxygen, non-invasive ventilation, invasive mechanical ventilation, or death by day 28, assessed in the intention-to-treat population. All-cause mortality by day 28 was a key secondary endpoint, and all-cause mortality by day 60 was an exploratory endpoint; both were assessed in the intention-to-treat population. Safety analyses were done in the safety population defined as all randomly allocated participants who received at least one dose of study drug and who were not lost to follow-up before the first post-baseline visit. This study is registered with ClinicalTrials.gov, NCT04421027.
FINDINGS: Between June 11, 2020, and Jan 15, 2021, 1525 participants were randomly assigned to the baricitinib group (n=764) or the placebo group (n=761). 1204 (79·3%) of 1518 participants with available data were receiving systemic corticosteroids at baseline, of whom 1099 (91·3%) were on dexamethasone; 287 (18·9%) participants were receiving remdesivir. Overall, 27·8% of participants receiving baricitinib and 30·5% receiving placebo progressed to meet the primary endpoint (odds ratio 0·85 [95% CI 0·67 to 1·08], p=0·18), with an absolute risk difference of -2·7 percentage points (95% CI -7·3 to 1·9). The 28-day all-cause mortality was 8% (n=62) for baricitinib and 13% (n=100) for placebo (hazard ratio [HR] 0·57 [95% CI 0·41-0·78]; nominal p=0·0018), a 38·2% relative reduction in mortality; one additional death was prevented per 20 baricitinib-treated participants. The 60-day all-cause mortality was 10% (n=79) for baricitinib and 15% (n=116) for placebo (HR 0·62 [95% CI 0·47-0·83]; p=0·0050). The frequencies of serious adverse events (110 [15%] of 750 in the baricitinib group vs 135 [18%] of 752 in the placebo group), serious infections (64 [9%] vs 74 [10%]), and venous thromboembolic events (20 [3%] vs 19 [3%]) were similar between the two groups.
INTERPRETATION: Although there was no significant reduction in the frequency of disease progression overall, treatment with baricitinib in addition to standard of care (including dexamethasone) had a similar safety profile to that of standard of care alone, and was associated with reduced mortality in hospitalised adults with COVID-19.
FUNDING: Eli Lilly and Company.
TRANSLATIONS: For the French, Japanese, Portuguese, Russian and Spanish translations of the abstract see Supplementary Materials section.
参考来源
- Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021. PMID: 34480861. doi:10.1016/S2213-2600(21)00331-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。